How often should men aged >65 years undergo prostate-specific antigen (PSA) testing?

PSA Testing Frequency for Men Over 65

For men over 65 who choose to undergo PSA screening after shared decision-making, testing should occur every 2-4 years, not annually—and screening should generally stop at age 70 unless the patient has exceptional health and life expectancy exceeding 10-15 years.

Age-Based Screening Recommendations

Men Aged 65-69 Years

• Continue screening every 2-4 years if the patient has previously chosen to participate in screening after informed discussion 1
• The US Preventive Services Task Force (2018) supports individualized screening decisions for men aged 55-69 years but recommends against screening for men ≥70 years 1
• The American College of Physicians (2015) explicitly recommends against screening in men aged ≥70 years 1

Men Aged 70 and Older

• Routine screening should be discontinued at age 70 for most men 1
• The only exception: highly selected healthy men with minimal comorbidity and life expectancy >10-15 years, where screening beyond age 75 may be considered with extreme caution 1
• Men over 75 years or those with life expectancy <10 years should not be offered screening due to substantial harms outweighing questionable benefits 2

Why Not Annual Screening?

There is no evidence supporting annual PSA testing. This is a critical point that contradicts common U.S. practice:

• The PLCO trial screened annually and found no mortality benefit 2
• The ERSPC trial, the only trial showing prostate cancer mortality reduction, screened men every 4 years (range 2-7 years) and demonstrated benefit 2
• Annual screening substantially increases harms: unnecessary biopsies, overdiagnosis, and overtreatment without improving outcomes 2

PSA-Based Interval Refinement

For men who continue screening between ages 65-69, the interval can be further individualized based on PSA level:

• PSA ≤1.0 ng/mL: Can extend interval to 3-4 years 3

  • These men have <3% chance of PSA >3 at next test
  • Only 5% of biopsied men had Gleason ≥7 cancer 3

• PSA >1.0 ng/mL: Consider 2-year intervals to balance cancer detection against false-positives 3

  • Longer intervals (>annual) associated with increased risk of higher Gleason score at diagnosis
  • However, annual testing increases false-positive biopsy recommendations 2-3 fold 3

Common Pitfalls to Avoid

1. Continuing annual screening in men over 70: This represents overscreening and leads to substantial harm from overdiagnosis in men unlikely to benefit 2, 1

2. Screening men with limited life expectancy: Men with <10 years life expectancy should not be screened regardless of age 2, 1

3. Failing to have the initial shared decision-making discussion: Two-thirds of U.S. men report no discussion about screening benefits, harms, or uncertainties 1

4. Assuming screening must be annual: This is not evidence-based and increases harm-to-benefit ratio 2

The Evidence Landscape

The guideline consensus is remarkably consistent across major organizations:

• US Preventive Services Task Force (2018): Against screening ≥70 years 1
• American College of Physicians (2015): Against screening ≥70 years 1
• American Urological Association (2015): Against routine screening with life expectancy <10-15 years 1
• European Association of Urology (2018): Against routine screening with life expectancy <15 years 1

While one retrospective study suggested benefit from annual screening 4, this contradicts the higher-quality randomized trial evidence and should not override guideline recommendations based on the ERSPC and PLCO trials 2.

Practical Algorithm

For men over 65:

1. Age 65-69 + life expectancy >10 years + prior informed consent: Screen every 2-4 years
2. Age 65-69 + PSA ≤1.0: Can extend to 3-4 years
3. Age 65-69 + PSA >1.0: Consider 2-year intervals
4. Age ≥70 OR life expectancy <10 years: Stop screening
5. Age >75 with exceptional health: Only consider screening after extensive discussion of limited benefit